Aspen targets 1mn patents in 2024, 4mn patents in 2026

Aspen’s latest agreement with Novo Nordisk, will allow for the local production of human insulin at its eastern cape-based sterile facility, aiming to supply vials to 4 million patients across Africa by 2026. The agreement also allows for critical technology and skills transfer to the region. Joining CNBC Africa for more is Stephen Saad, CEO, Aspen.
Wed, 20 Sep 2023 16:59:53 GMT